NLS Pharmaceutics Ltd. NLSPW
Set alert
0.02 USD 0.00 0.00%
At close · Oct 28
Day range unavailable
52-week range unavailable
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- —
- Prev close
- 0.0179
- Mkt cap
- 7.43K
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 0.00
- Beta
- -0.52
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.01222
- 200-d avg
- 0.02651
- 1y target
- 0.00
News
-
1 year ago benzinga.com
NLS Pharma And Aexon Labs Expand DOXA Platform With AEX-6xx Series, New Generation Of Small Molecules Targeting Arousal Stability, Cognition, And Neuroprotection
DOXA Platform Expansion Strengthens Cognitive, Arousal, and Neuroprotective ProgramsSupported by Solid Cash Position and Strategic Funding OutlookZURICH, Oct. 30, 2025 /PRNewswire/ -- NLS…
-
1 year ago benzinga.com
NLS Pharmaceutics, Kadimastem Receive Approval To List Common Shares On Nasdaq After Merger Under NewcelX Name, NCEL Ticker
NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system ("CNS") disorders, and Kadimastem Ltd.…